This is a pre-revenue biotech with no quarterly earnings surprise to trade. The stock will move on ANB033 Phase 1b data readouts — celiac disease in Q4 2026 and eosinophilic esophagitis in mid-2027. Monitor for partnership announcements on rosnilimab, which management is actively pursuing. No near-term catalyst from this filing.
Price Chart
Executive Summary
First Tracks Biotherapeutics reported a net loss of $50.5M for Q1 2026, wider than the $47.2M loss in Q1 2025, as a clinical-stage biotech with no revenue. The company launched on April 20 with $180M cash runway to fund ANB033 Phase 1b data in celiac disease (Q4 2026) and eosinophilic esophagitis (mid-2027). The wider loss and absence of revenue make this a routine pre-revenue biotech update — the stock will trade on pipeline catalysts, not quarterly financials.
Key Facts
- Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025
- Launched with $180M cash and cash equivalents on April 20, 2026
- ANB033 Phase 1b celiac disease top-line data expected Q4 2026
- ANB033 Phase 1b eosinophilic esophagitis top-line data expected mid-2027
- Completed End-of-Phase 2 meeting with FDA for rosnilimab in rheumatoid arthritis
- Research and development expenses decreased to $34.0M from $41.5M YoY
- General and administrative expenses increased to $18.9M from $9.8M YoY due to separation costs
- No revenue reported — pre-revenue clinical-stage biotech
Financial Impact
Net loss widened by $3.3M YoY to $50.5M; cash position $248.5M at March 31, 2026, plus $180M post-separation launch capital
Risk Factors
- Clinical trial failure risk for ANB033 in celiac disease or eosinophilic esophagitis
- Cash runway of ~2 years may require dilutive financing if trials extend or additional programs are added
- No revenue or near-term commercialization prospects
- Rosnilimab strategic options may not materialize into a favorable partnership
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-224124 |
| Document: trax-20260514.htm | 0001193125-26-224124 |
| Document: 0001193125-26-224124-index-headers.html | 0001193125-26-224124 |
| Document: 0001193125-26-224124-index.html | 0001193125-26-224124 |
| Document: 0001193125-26-224124.txt | 0001193125-26-224124 |
| 8-K Data (Synthetic) | 0001193125-26-224124 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers